Navigation Links
Cypress Bioscience Board of Directors to Review Unsolicited Tender Offer from Ramius LLC
Date:9/15/2010

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Cypress Bioscience, Inc. (Nasdaq: CYPB)  ("Cypress") today confirmed that Ramius LLC ("Ramius") has commenced an unsolicited tender offer to acquire all outstanding common shares of Cypress at a price of $4.25 per share in cash.

Consistent with its fiduciary duties and as required by applicable law, the Cypress Board of Directors will review the offer to determine the course of action that it believes is in the best interests of the Company and its stockholders.  Cypress stockholders are advised to take no action at this time pending the review of the tender offer by the Cypress Board of Directors.

Jefferies & Company, Inc. and Perella Weinberg Partners are serving as financial advisors to Cypress and Cooley LLP and Potter Anderson & Corroon LLP are serving as its legal advisors.

The Cypress Board of Directors, in consultation with its independent financial and legal advisors, intends to advise stockholders of its formal position regarding the offer within ten business days by making available to stockholders and filing with the Securities and Exchange Commission a solicitation/recommendation statement on Schedule 14D-9.

About Cypress Bioscience

Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system.  Since 1999, Cypress has received multiple FDA approvals, including for Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia.  The Company focuses on generating stockholder value by reaching clinical development milestones as quickly and efficiently as possible.  Cypress' currently marketed products include Savella and the Avise PGSM and Avise MCVSMtherapeutic monitoring, diagnostic and prognostic testing services for rheumatoid arthritis.  Development-stage assets include CYP-1020 for cognitive impairment in schizophrenia, Staccato® nicotine for smoking cessation, intranasal carbetocin for autism, and AVISE-SLESM, a lupus diagnostic testing service.  More information on Cypress and its products and development assets is available at http://www.cypressbio.com.INVESTOR CONTACTS:MEDIA CONTACTS:MacKenzie Partners, Inc.

Joele Frank, Wilkinson Brimmer KatcherAmy Bilbija / Bob Marese

Sharon Stern / Dara Silverstein650-798-5206 / 212-929-5500

212-355-4449
'/>"/>

SOURCE Cypress Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
3. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017   Royal Philips ... in health technology, and PathAI, a company that ... with the aim to develop solutions that improve ... cancer and other diseases. The partnership aims to ... this form of artificial intelligence to be applied ...
(Date:3/29/2017)... NetworkNewsWire Editorial Coverage  ... There are a number of advantages ... economic arguments also favor its legalization. The benefits include increased ... to legalize and regulate marijuana requires an ecosystem of support ... SING Profile ), American Cannabis Company (OTC: AMMJ), Kush Bottles, ...
(Date:3/29/2017)... , March 29, 2017 FinancialBuzz.com News Commentary  ... Data published in a research ... market will reach a value of USD 55.8 billion by 2025. The ... the United States and a more open approach towards cannabis ... , Florida , North Dakota , ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... in order to improve teacher quality, the field must first improve teacher preparation ... popular reform to the next” and that decades of input- and outcome-based research ...
(Date:3/28/2017)... ... 28, 2017 , ... For many women, getting birth control isn’t as easy as it should ... don’t have access to a health care facility or a pharmacy within 60 minutes of ... United States or for many who are faced with health or personal issues that leave ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors is expanding ... extensive knowledge of appraisals, property values, ad valorem taxation, and government policy to ... for more than 40 years. , “Ruel is a great addition to the ...
(Date:3/28/2017)... WASHINGTON, DC (PRWEB) , ... March 28, 2017 ... ... call on elected representatives in state legislatures and Congress to protect parental rights ... the public health and safety in America. , The demonstration coincides with a ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of the world, ... talked about journey and research recently on a blog and discussed some major aspects ... to deal with thyroid disease. , Dr. Wentz completed her graduation from the ...
Breaking Medicine News(10 mins):